Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts.
暂无分享,去创建一个
G. Paolisso | R. Marfella | G. Signoriello | P. Golino | Vincenzo Grimaldi | C. Maiello | Lucia Scisciola | C. Sardu | Cristiano Amarelli | G. Mansueto | C. Napoli | N. D'Onofrio | M. Balestrieri | S. Esposito | M. D'Amico | M. Trotta | N. D’Onofrio | Marisa De Feo | L. Scisciola
[1] G. Santulli,et al. SGLT2 Inhibitors in Cardiovascular Medicine. , 2021, European heart journal. Cardiovascular pharmacotherapy.
[2] Guanwei Fan,et al. SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism , 2021, Heart Failure Reviews.
[3] G. Qin,et al. Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2021, Frontiers in Endocrinology.
[4] M. Jardine,et al. SGLT2 inhibitors may offer benefit beyond diabetes , 2020, Nature Reviews Nephrology.
[5] K. Node,et al. How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition? , 2020, Cardiovascular Diabetology.
[6] C. Napoli,et al. Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development , 2020, Journal of the American Heart Association.
[7] Abdul Waheed Khan,et al. Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD , 2020, Circulation research.
[8] Sandeep R. Das,et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2020, Journal of the American College of Cardiology.
[9] X. Qu,et al. Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes , 2020, Frontiers in Endocrinology.
[10] C. Napoli,et al. Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients. , 2020, Journal of the American College of Cardiology.
[11] A. Akhmedov,et al. Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy , 2019, European heart journal.
[12] S. Verma,et al. Empagliflozin Increases Cardiac Energy Production in Diabetes , 2018, JACC. Basic to translational science.
[13] J. Sowers,et al. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity , 2018, Circulation research.
[14] J. Shaw,et al. Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. , 2018, Journal of the American College of Cardiology.
[15] B. Gerber,et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging , 2017, European heart journal cardiovascular Imaging.
[16] Gerasimos S Filippatos,et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.
[17] G. Paolisso,et al. Ergothioneine oxidation in the protection against high-glucose induced endothelial senescence: Involvement of SIRT1 and SIRT6. , 2016, Free radical biology & medicine.
[18] K. Tsuchiya,et al. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction , 2016, PloS one.
[19] L. Badano,et al. European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation. , 2015, European heart journal cardiovascular Imaging.
[20] V. Fuster,et al. The relationships between cardiovascular disease and diabetes: focus on pathogenesis. , 2014, Endocrinology and metabolism clinics of North America.
[21] W. Garvey,et al. Limitations in the Use of Indices Using Glucose and Insulin Levels to Predict Insulin Sensitivity , 2013, Diabetes Care.
[22] C. Pollock,et al. Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy? , 2013, PloS one.
[23] G. Paolisso,et al. Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation , 2012, Diabetologia.
[24] S. Park,et al. Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in Korea. , 2005, Metabolism: clinical and experimental.
[25] Jennifer Y. Liu,et al. Glycemic Control and Heart Failure Among Adult Patients With Diabetes , 2001, Circulation.